The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.80
Ask: 3.84
Change: 0.09 (2.43%)
Spread: 0.04 (1.053%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.71
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Divestment of non-core subsidiary

25 Nov 2013 15:15

RNS Number : 8697T
Plant Health Care PLC
25 November 2013
 



 

 

 

 

25 November 2013

 

PLANT HEALTH CARE PLC

 

("Plant Health Care" or the "Company")

 

Divestment of non-core subsidiary

 

Plant Health Care (AIM / CISX: PHC), a leading provider of novel patent protected biological products to the global agriculture markets, announced a new strategy in March 2013, to create a business focused on accelerating the research and development of its Harpin technology platform and maximising sales of the current Harpin and Myconate products over the next three years (the "Strategy").

 

As part of the implementation of the Strategy, Plant Health Care today announces it has entered into an agreement for the divestment of the Company's wholly-owned Netherlands subsidiary, Plant Health Care BV (the "Subsidiary"), to the management of the Subsidiary under the leadership of Mr. Pius Floris (the "Disposal"). The Disposal, which will result in the divestment of the Company's European distribution businesses, involves the sale of the Subsidiary and the sale to the Subsidiary of all inventory (except that of Harpin and Myconate) currently held by the Company's Spanish and UK subsidiaries, valued at approximately US$19,956 and US$89,193 respectively. It is expected the Subsidiary will change its name in the next 12 months. The consideration for the Disposal is €1 and the repayment of an outstanding inter-company loan of approximately US$536,230. This will result in a write-off of approximately US$281,472 to Plant Health Care.

 

In the six months ended 30 June 2013, the Subsidiary had total sales of US$1,070,560 (year ended 31 December 2012: US$1,552,260), of which Harpin and Myconate represented approximately 4 percent. In the six months ended 30 June 2013, the Subsidiary made profits before tax of US$173,439 (year ended 31 December 2012: US$7,214).

 

Proceeds from the Disposal will be retained for working capital purposes and for continued implementation of the Company's Strategy.

 

The Company retains all rights to the distribution of Harpin and Myconate and of all future Plant Health Care products. It is the Company's intention to continue to invest further in the marketing and distribution of these products across Europe, using its existing international distribution capability in the UK. The Disposal will enable the Company to focus its resources on implementing the Strategy and creating value for its shareholders.

 

Related Party Opinion

 

In view of Mr. Pius Floris being a director of the Subsidiary, and the majority owner of the Subsidiary following completion of the Disposal, the transaction constitutes a related party transaction under the AIM Rules. The Directors consider, having consulted with the Company's nominated adviser, Liberum Capital, that the terms of the Disposal are fair and reasonable in so far as the Company's shareholders are concerned.

 

Commenting on the Transaction, Mr Paul Schmidt, CEO of Plant Health Care, said:

 

"I am delighted that we have reached an agreement to divest these businesses to Pius and his team. This divestment leaves Plant Health Care a much more focused business, better able to drive the development of our core products and technologies, in line with our strategy. We thank Pius for 14 years of dedicated service to Plant Health Care and wish him well in his new endeavour."

 

- ENDS -

For further information, please contact:

Plant Health Care plc

Paul Schmidt, Chief Executive Officer

Tel: +1-919-926-1600

Liberum Capital - Nomad and Broker

Clayton Bush / Thomas Bective

Tel: +44 (0) 20 3100 2222

Powerscourt

Sophie Moate / Nick Dibden

Tel: +44 (0) 20 7250 1446

Company website: www.planthealthcare.com

 

About Plant Health Care: Plant Health Care is a leading provider of patent protected biological products aimed at the agriculture industry that are environmentally beneficial. Through the commercialisation of these products, Plant Health Care is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBABATMBMTBIJ
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.